Management of Small Pulmonary Embolism with Apixaban Failure

Immediate Assessment and Management

The European Society of Cardiology recommends switching to therapeutic low molecular weight heparin (LMWH) or unfractionated heparin immediately, and investigating the underlying cause of anticoagulation failure before considering escalation to thrombolysis or alternative interventions 1
Confirming medication adherence is crucial, as non-compliance is the most common cause of apparent anticoagulation failure, according to the European Heart Journal 2
Assessing renal and hepatic function is essential, as apixaban metabolism depends on both, and deterioration can lead to subtherapeutic levels, as stated by the European Heart Journal 1, 2
Checking for drug-drug interactions, particularly with CYP3A4 and P-glycoprotein inducers that reduce apixaban levels, is necessary, as recommended by the European Heart Journal 2
Excluding severe renal impairment (CrCl <30 mL/min) or antiphospholipid antibody syndrome, both absolute contraindications to NOACs, is vital, according to the European Heart Journal 1

Systemic thrombolysis is indicated if systolic blood pressure <90 mmHg or cardiogenic shock develops, as recommended by the European Heart Journal 3, 1
The European Heart Journal suggests using rtPA 100 mg over 2 hours as first-line thrombolytic 3, 4
Surgical embolectomy is recommended if thrombolysis is contraindicated or fails, according to the European Heart Journal 3, 1

The European Heart Journal states that LMWH is superior to NOACs in cancer patients and should be continued indefinitely while cancer is active 3, 1
Testing for antiphospholipid antibody syndrome is necessary, as it requires lifelong warfarin, not NOACs, as recommended by the European Heart Journal 1
Considering other thrombophilias in unprovoked or recurrent pulmonary embolism is essential, according to Thorax 4

The European Heart Journal recommends continuing indefinite anticoagulation if recurrent venous thromboembolism (at least one prior episode) is not related to reversible risk factor 1, 2
Continuing indefinite anticoagulation for unprovoked pulmonary embolism after weighing bleeding risk is necessary, as stated by the European Heart Journal 1, 2
Discontinuing anticoagulation after 3 months is only recommended if provoked by major transient/reversible risk factor, according to the European Heart Journal 1, 2

Warfarin (INR 2.0-3.0) is appropriate if switching from failed NOAC, particularly in antiphospholipid syndrome, as recommended by the European Heart Journal 1, 4
Extended LMWH monotherapy is a feasible alternative to warfarin, especially in cancer, according to the European Heart Journal 3

Reassessing at 3-6 months after the acute event for symptoms, functional status, and need for continued anticoagulation is necessary, as recommended by the European Heart Journal 1, 2
Regular evaluation of bleeding risk, renal/hepatic function, and adherence for patients on extended therapy is essential, according to the European Heart Journal 1, 2